June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Pigment Epithelial Derived Factor ameliorates dry eye disease by promoting regulatory T-cell mediated suppression of Th17 immune response
Author Affiliations & Notes
  • Rohan Bir Singh
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Tomas Blanco
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Hamid Alemi
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Yihe Chen
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Sunil Chauhan
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Reza Dana
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Rohan Singh, None; Tomas Blanco, None; Hamid Alemi, None; Yihe Chen, None; Sunil Chauhan, None; Reza Dana, None
  • Footnotes
    Support  NIHR01EY20889 (RD), NIHP30Y003790 (Core Grant)
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1960. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rohan Bir Singh, Tomas Blanco, Hamid Alemi, Yihe Chen, Sunil Chauhan, Reza Dana; Pigment Epithelial Derived Factor ameliorates dry eye disease by promoting regulatory T-cell mediated suppression of Th17 immune response. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1960.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : PEDF is ubiquitously expressed 50kD protein with myriad anti-inflammatory functions. In this study, we determined the effect of recombinant PEDF(rPEDF) on dysfunctional Tregs in dry eye disease(DED).

Methods : MACS sorted CD4+CD25+ T-cells from draining lymph nodes(dLNs) of C57BL/6 mice with DED (induced in controlled environment chamber for 7 days) were cultured with/without rPEDF for 72 hrs. We evaluated Treg(CD4+CD25+FoxP3+ T-cells)frequency and suppressive phenotype by examining expression levels(MFI) of FoxP3, CTLA-4 & GITR using flow cytometry (FC) and mRNA expression levels of IL10 & TGFβ (Treg-associated cytokines) using RT-PCR. We assessed the neutralizing effect of rPEDF on pro-inflammatory cytokine-IL-17A, IFNγ(expressed by CD4+Th17 cells) induced Treg dysfunction, by evaluating Treg frequency and expression of above-mentioned markers with FC & RT-PCR after 72 hrs of co-culture. We treated DED mice(14 days induction) with i.p. injection of 1 µg/ml rPEDF or control(Murine Serum Albumin, MSA) q.d. from day 7. We assessed disease severity by corneal fluorescein staining(CFS), performed FC on dLNs of treated mice to examine changes in Treg frequency and MFI of associated markers.

Results : The data demonstrated a significantly higher Treg frequency(p=0.001) and expression of FoxP3(p=0.0263),CTLA-4,(p=0.0101),GITR(p=0.0245) and higher mRNA expression of IL10 & TGFβ(p=0.0011,p=0.0009) by Tregs on addition of rPEDF to co-culture. rPEDF reversed the effect of IL-17A, IFNγ induced dysfunction in Tregs by significantly increasing the Treg frequency(p=0.0013),expression of FoxP3(p=0.0001),CTLA-4(p=0.0013),GITR(p=0.019) and significantly higher mRNA expression of IL10 & TGFβ(p=0.002,p=0.005). We observed significant reduction in CFS scores in rPEDF treated mice compared to controls(p=0.05). FC data showed significantly higher Treg frequency(p=0.0002) and expression of FoxP3(p=0.025) in dLNs of rPEDF treated mice compared to controls.

Conclusions : Our results suggest that rPEDF maintains Treg function in-vitro and nullifies the dysfunctional effect of IL-17A, IFNγ. Our in-vivo data showed a higher Treg frequency and function on rPEDF treatment that may be contributing to disease amelioration. These findings indicate a potential therapeutic role of PEDF associated with promoting regulatory T cell-mediated suppression of Th17 immune response in dry eye disease.

This is a 2020 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×